Patents by Inventor Christopher Austin Darby

Christopher Austin Darby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10925957
    Abstract: Co-administration (for example, immunogenic cocktail compositions and/or prime boost regimens) of computationally optimized H1N1 influenza hemagglutinin (HA) polypeptides is provided. Coadministration of the optimized H1N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (for example, a broad reactive immune response) to diverse and multiple H1N1 influenza virus strains, including both seasonal and pandemic strains.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: February 23, 2021
    Assignees: OREGON HEALTH & SCIENCE UNIVERSITY, SANOFI PASTEUR, INC.
    Inventors: Ted Milburn Ross, Tim Alefantis, Donald Martin Carter, Jr., Christopher Austin Darby, Harold Kleanthous
  • Patent number: 10548965
    Abstract: The present invention provides co-administration (e.g., immunogenic cocktail and/or prime-boost regimens) of computationally optimized H5N1 influenza hemagglutinin (HA) polypeptides that. Co-administration of the optimized H5N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (e.g., a broad reactive immune response) to multiple H5N1 influenza virus clades and strains.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 4, 2020
    Assignees: Oregon Health & Science University, Sanofi Pasteur, Inc.
    Inventors: Ted Milburn Ross, Tim Alefantis, Donald Martin Carter, Christopher Austin Darby, Harold Kleanthous
  • Publication number: 20190175721
    Abstract: The present invention provides co-administration (for example, immunogenic cocktail compositions and/or prime-boost regimens) of computationally optimized H1N1 influenza hemagglutinin (HA) polypeptides. Co-administration of the optimized H1N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (e.g., a broad reactive immune response) to diverse and multiple H1N1 influenza virus strains, including both seasonal and pandemic strains.
    Type: Application
    Filed: January 25, 2019
    Publication date: June 13, 2019
    Inventors: Ted Milburn Ross, Tim Alefantis, Donald Martin Carter, JR., Christopher Austin Darby, Harold Kleanthous
  • Publication number: 20190111126
    Abstract: The present invention provides co-administration (e.g., immunogenic cocktail and/or prime-boost regimens) of computationally optimized H5N1 influenza hemagglutinin (HA) polypeptides that. Co-administration of the optimized H5N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (e.g., a broad reactive immune response) to multiple H5N1 influenza virus clades and strains.
    Type: Application
    Filed: December 18, 2015
    Publication date: April 18, 2019
    Inventors: Ted Milburn Ross, Tim Alefantis, Donald Martin Carter, Christopher Austin Darby, Harold Kleanthous
  • Patent number: 10220086
    Abstract: The present invention provides co-administration (for example, immunogenic cocktail compositions and/or prime-boost regimens) of computationally optimized H1N1 influenza hemagglutinin (HA) polypeptides. Co-administration of the optimized H1N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (e.g., a broad reactive immune response) to diverse and multiple H1N1 influenza virus strains, including both seasonal and pandemic strains.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: March 5, 2019
    Assignees: OREGON HEALTH & SCIENCE UNIVERSITY, SANOFI PASTEUR, INC.
    Inventors: Ted Milburn Ross, Tim Alefantis, Donald Martin Carter, Christopher Austin Darby, Harold Kleanthous
  • Publication number: 20170368164
    Abstract: The present invention provides co-administration (for example, immunogenic cocktail compositions and/or prime-boost regimens) of computationally optimized H1N1 influenza hemagglutinin (HA) polypeptides. Co-administration of the optimized H1N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (e.g., a broad reactive immune response) to diverse and multiple H1N1 influenza virus strains, including both seasonal and pandemic strains.
    Type: Application
    Filed: December 18, 2015
    Publication date: December 28, 2017
    Inventors: Ted Milburn Ross, Tim Alefantis, Donald Martin Carter, Christopher Austin Darby, Harold Kleanthous